The Shuman Law Firm Investigates Dynavax Technologies Corp.
18 April 2015 - 2:13AM
Business Wire
The Shuman Law Firm announces that it is investigating potential
claims against certain officers and directors of Dynavax
Technologies Corp. (“Dynavax” or the “Company”) (Nasdaq: DVAX).
Dynavax is a California based clinical-stage biopharmaceutical
company.
The Firm’s investigation relates to potential damages to Dynavax
caused by allegedly false and misleading public statements by the
Company’s senior officers and directors regarding Dynavax’s
Hepatitis B vaccine, “HEPISLAV”. These alleged false and misleading
statements, when made public, led to the drop in Dynvax’s stock
price and the filing of a class action lawsuit against the Company.
Recently, a federal judge denied, in part, the Company’s motion to
dismiss the class action lawsuit and the case is now proceeding
toward trial.
If you currently own Dynavax common stock and are interested in
discussing your rights, or have information relating to this
investigation, please contact Kip B. Shuman or Rusty E. Glenn
toll-free at (866) 569-4531 or email Mr. Shuman at
kip@shumanlawfirm.com or email Mr. Glenn at
rusty@shumanlawfirm.com.
The Shuman Law Firm represents investors throughout the nation,
concentrating its practice in stockholder litigation.
The Shuman Law FirmKip B. Shuman, Esq.,
303-861-3003kip@shumanlawfirm.comorRusty E. Glenn, Esq.,
303-861-3003rusty@shumanlawfirm.comorToll-Free: 866-569-4531Fax:
303-536-7849www.shumanlawfirm.com
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2024 to May 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From May 2023 to May 2024